PFIZER CEO CONFIRMS CELENTE FORECAST: RETURN TO NORMAL LIFE BY SPRING

In Gerald Celente’s letter to subscribers last week, he had forecast “… as businesses sink deeper in debt and economies decline as interest rates and inflation rise, we forecast the COVID War will begin to wind-down late March, mid-April. 
Picking up where Celente left off, yesterday, the CEO of Pfizer said he sees a return to “normal life” in the spring.
His reason is that “We will soon be able to go back to a normal life,” because new treatments will help prevent severe illness.
He called Paxlovid, his company’s antiviral drug, a “game-changer.” Paxlovid and Merck’s Molnupiravir are intended to be used after someone becomes infected.
Paxlovid was authorized by U.S. health regulators last month and saw a 90 percent reduction of hospitalizations and deaths among patients most likely to come down with a severe illness. 
The news is welcome given that a study which we note in this Trends Journal that the fourth booster shot being injected into Israelis did little to prevent Omicron infection. 
Gili Regev-Yochay, the director of Israel’s Sheba Medical Center’s Infectious Diseases Unit, said the fourth Pfizer dose led to more antibodies—even more than produced in the third booster—but it is probably not enough for the Omicron variant.
Her comment is striking because health officials have been telling the public that only a third jab provides protection against the Omicron variant. (See “BIDEN’S BOOSTER PLAN: VAX YOU,” “SELLING BOOSTER SHOTS, CDC’S WALENSKY SAYS ‘FU’ TO AGENCY ADVISERS,” “THE VAX/BOOSTER MARKET: DRUG DEALER ON PARADE” and “NEW YORK DICTATOR: NO BOOSTER SHOT, NO JOB.”)
Stéphane Bancel, the CEO of Moderna, told reporters on Monday that his company plans to market a COVID-19/influenza vaccine by fall 2023.
“Our goal is to be able to have a single annual booster so that we don’t have compliance issues where people don’t want to get two to three shots a winter,” he told a panel at the World Economic Forum, according to Politico. “The best-case scenario would be the fall of 2023.”
TREND FORECAST: New vax drugs or not, we forecast the COVID War will begin winding-down late March, mid-April. 
The protests raging across Europe, the January 23rd mass-march targeting Washington DC, the loss of businesses and the destruction of hundreds of millions—if not billions—of lives and livelihoods that have been sacrificed to fight the COVID War, has reached its pivot point.